| Literature DB >> 30909759 |
Enrico Papini1, Claudio Maurizio Pacella2, Luigi Alessandro Solbiati3,4, Gaetano Achille5, Daniele Barbaro6, Stella Bernardi7,8, Vito Cantisani9, Roberto Cesareo10, Arturo Chiti3,4, Luca Cozzaglio4, Anna Crescenzi11, Francesco De Cobelli12, Maurilio Deandrea13, Laura Fugazzola14,15, Giovanni Gambelunghe16, Roberto Garberoglio17, Gioacchino Giugliano18, Livio Luzi15,19, Roberto Negro20, Luca Persani14,15, Bruno Raggiunti21, Francesco Sardanelli15,22, Ettore Seregni23, Martina Sollini3, Stefano Spiezia24, Fulvio Stacul7, Dominique Van Doorne25, Luca Maria Sconfienza15,26, Giovanni Mauri27.
Abstract
Benign thyroid nodules are a common clinical occurrence and usually do not require treatment unless symptomatic. During the last years, ultrasound-guided minimally invasive treatments (MIT) gained an increasing role in the management of nodules causing local symptoms. In February 2018, the Italian MIT Thyroid Group was founded to create a permanent cooperation between Italian and international physicians dedicated to clinical research and assistance on MIT for thyroid nodules. The group drafted this list of statements based on literature review and consensus opinion of interdisciplinary experts to facilitate the diffusion and the appropriate use of MIT of thyroid nodules in clinical practice. (#1) Predominantly cystic/cystic symptomatic nodules should first undergo US-guided aspiration; ethanol injection should be performed if relapsing (level of evidence [LoE]: ethanol is superior to simple aspiration = 2); (#2) In symptomatic cystic nodules, thermal ablation is an option when symptoms persist after ethanol ablation (LoE = 4); (#3) Double cytological benignity confirmation is needed before thermal ablation (LoE = 2); (#4) Single cytological sample is adequate in ultrasound low risk (EU-TIRADS ≤3) and in autonomously functioning nodules (LoE = 2); (#5) Thermal ablation may be proposed as first-line treatment for solid, symptomatic, nonfunctioning, benign nodules (LoE = 2); (#6) Thermal ablation may be used for dominant lesions in nonfunctioning multinodular goiter in patients refusing/not eligible for surgery (LoE = 5); (#7) Clinical and ultrasound follow-up is appropriate after thermal ablation (LoE = 2); (#8) Nodule re-treatment can be considered when symptoms relapse or partially resolve (LoE = 2); (#9) In case of nodule regrowth, a new cytological assessment is suggested before second ablation (LoE = 5); (#10) Thermal ablation is an option for autonomously functioning nodules in patients refusing/not eligible for radioiodine or surgery (LoE = 2); (#11) Small autonomously functioning nodules can be treated with thermal ablation when thyroid tissue sparing is a priority and ≥80% nodule volume ablation is expected (LoE = 3).Entities:
Keywords: Statement; minimally invasive treatments; percutaneous thermal ablation; thyroid gland; thyroid nodule; ultrasonography
Mesh:
Year: 2019 PMID: 30909759 DOI: 10.1080/02656736.2019.1575482
Source DB: PubMed Journal: Int J Hyperthermia ISSN: 0265-6736 Impact factor: 3.914